Literature DB >> 22537114

Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.

Naoki Niikura1, Takayuki Iwamoto, Shinobu Masuda, Nobue Kumaki, Tang Xiaoyan, Masatoshi Shirane, Kazushige Mori, Banri Tsuda, Takuho Okamura, Yuki Saito, Yasuhiro Suzuki, Yutaka Tokuda.   

Abstract

The objective of this study was to examine the association between the immunohistochemical Ki67 labeling index (IHC Ki67), Ki67 mRNA expression level, and first-generation gene signatures in a cohort of breast cancer patients. We assessed associations between IHC Ki67 and first-generation gene signatures in a panel of 39 tumor samples, using an oligonucleotide microarray. Gene expression analyses included Ki67 alone (MKi67), 21-gene signature, mitosis kinome score signature, and genomic grade index. Correlation coefficients were calculated by Spearman's rank correlation test. In all cases, IHC Ki67, MKi67, and three genetic markers were highly correlated (ρ, 0.71-0.97). Estrogen receptor (ER)-positive cases showed strong correlations between IHC Ki67 and other signatures (ρ, 0.79-0.83). The ER-negative cases showed slightly lower correlations (ρ, 0.58-0.73). In ER-positive cases, the low IHC Ki67 group showed significantly longer relapse-free survival than the high IHC Ki67 group (P = 0.007). This difference was confirmed by multivariate analysis. Our data indicate that IHC Ki67 shows similar predictive power for proliferation in ER-positive cancers as genomic markers. Further study of IHC Ki67 is needed to define prognostic factors and predictive factors for chemotherapy using central laboratory assessment.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22537114     DOI: 10.1111/j.1349-7006.2012.02319.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  23 in total

1.  Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Jason R Brown; Michael P DiGiovanna; Brigid Killelea; Donald R Lannin; David L Rimm
Journal:  Lab Invest       Date:  2013-11-04       Impact factor: 5.662

2.  Quality assurance trials for Ki67 assessment in pathology.

Authors:  M Raap; S Ließem; J Rüschoff; A Fisseler-Eckhoff; A Reiner; S Dirnhofer; R von Wasielewski; H Kreipe
Journal:  Virchows Arch       Date:  2017-05-11       Impact factor: 4.064

3.  Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.

Authors:  Nicholas P Tobin; Linda S Lindström; Joseph W Carlson; Judith Bjöhle; Jonas Bergh; Kristian Wennmalm
Journal:  Mol Oncol       Date:  2014-02-28       Impact factor: 6.603

4.  Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401).

Authors:  Tadahiko Shien; Hiroji Iwata; Kenjiro Aogi; Takashi Fukutomi; Kenichi Inoue; Takayuki Kinoshita; Masato Takahashi; Akira Matsui; Taro Shibata; Haruhiko Fukuda
Journal:  Int J Clin Oncol       Date:  2014-01-07       Impact factor: 3.402

5.  High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.

Authors:  Emilio Alba; Ana Lluch; Nuria Ribelles; Antonio Anton-Torres; Pedro Sanchez-Rovira; Joan Albanell; Lourdes Calvo; Jose Antonio Lopez García-Asenjo; Jose Palacios; Jose Ignacio Chacon; Amparo Ruiz; Juan De la Haba-Rodriguez; Miguel A Segui-Palmer; Beatriz Cirauqui; Mireia Margeli; Arrate Plazaola; Agusti Barnadas; Maribel Casas; Rosalia Caballero; Eva Carrasco; Federico Rojo
Journal:  Oncologist       Date:  2016-01-19

6.  Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases.

Authors:  Jing Liu; Yaming Wang; Yuantao Liu; Zhe Liu; Qu Cui; Nan Ji; Shengjun Sun; Bingxu Wang; Yajie Wang; Xuefei Sun; Yuanbo Liu
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

Review 7.  Breast cancer metastasis: issues for the personalization of its prevention and treatment.

Authors:  Natascia Marino; Stephan Woditschka; L Tiffany Reed; Joji Nakayama; Musa Mayer; Maria Wetzel; Patricia S Steeg
Journal:  Am J Pathol       Date:  2013-07-26       Impact factor: 4.307

8.  Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.

Authors:  Arian Lundberg; Linda S Lindström; J Chuck Harrell; Claudette Falato; Joseph W Carlson; Paul K Wright; Theodoros Foukakis; Charles M Perou; Kamila Czene; Jonas Bergh; Nicholas P Tobin
Journal:  Clin Cancer Res       Date:  2017-09-29       Impact factor: 12.531

9.  An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer.

Authors:  Ruohong Shui; Baohua Yu; Rui Bi; Fei Yang; Wentao Yang
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

10.  Overexpression of N-myc downstream-regulated gene 1 inhibits human glioma proliferation and invasion via phosphoinositide 3-kinase/AKT pathways.

Authors:  Wei Ma; Meng Na; Chongyang Tang; Haiyang Wang; Zhiguo Lin
Journal:  Mol Med Rep       Date:  2015-03-13       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.